1.Primary non-Hodgkin lymphoma in the female genital system: a report of 28 cases.
Yi HU ; Feng-Yi FENG ; Pin ZHANG ; Li-Qiang ZHOU ; Wen-Hua ZHANG ; Qi-Lu WANG
Chinese Journal of Oncology 2003;25(5):486-489
OBJECTIVETo evaluate the clinical characteristics, results of treatment, and prognostic factors of patients diagnosed as having primary female genital system lymphoma (PFGSL).
METHODSTwenty-eight cases of PFGSL were retrospectively surveyed and the clinical data of the patients were analyzed by statistic software package of SPSS10.0 for relation between clinical stage, grade, pathologic feature, treatment and prognosis.
RESULTSThe median age was 44 in the cohort. It mainly involved cervix uterus, ovary and vulva. The disease had a broad range of pathologic type and 20 patients were diagnosed as suffering from B-cell by immunophenotyping, 4 patients were diagnosed as T-cell and 4 patients lesions were indefinite. According to International Working Formulation (IWF), 66.7% belonged to the intermediate-grade. The Ann Arbor stage included: Stage I(E)-12 pts (42.86%), Stage II(E)-3 pts (10.7%), Stage III(E)-1 pts (3.6%) and Stage IV-12 pts (42.86%). According to International Prognostic Index (IPI), 10 were low risk, 9 low-medium risk, 3 medium-high risk and 6 high risk, The median follow-up of the surviving patients was 2.0 years (range: 3 months-17 years), The 5-year overall survival rate was 39.3%. Most patients were given comprehensive treatment without any mode showing significant advantage over the others in survival (P = 0.2554), The involved organs, Ann Arbor stage, IWF and also IPI were significant prognostic factors for survival,
CONCLUSIONThe management of PFGSL should be based on comprehensive treatment including chemotherapy as the chief means. The significant prognostic factors of survival is Ann Arbor stage, IPI, IWF and the kind of involved organs.
Adolescent ; Adult ; Aged ; Child ; Female ; Genital Neoplasms, Female ; mortality ; pathology ; therapy ; Humans ; Lymphoma, Non-Hodgkin ; mortality ; pathology ; therapy ; Middle Aged ; Retrospective Studies ; Survival Rate
2.Eleven-Year Experience of Low Grade Lymphoma in Korea (Based on REAL Classification) .
Jee Sook HAHN ; Yong Soo KIM ; Yong Chan LEE ; Woo Ick YANG ; Sang Yeal LEE ; Chang Ok SUH
Yonsei Medical Journal 2003;44(5):757-770
Low grade lymphomas are malignancies of predominantly small lymphocytes that typically have long median survival periods due to low proliferative rates. It is considered an indolent disease, but patients with low grade lymphoma can almost never be cured with conventional treatment. New low-grade lymphoma entities have been classified by the International Lymphoma Study Group (ILSG) and are also categorized into the Revised European American Lymphoma (REAL) classification. The REAL classification utilizes a multiparameter definition of clinico-pathologic and biologic entities. According to this classification, we investigated the incidence, various clinical characteristics, treatment outcome and prognostic factors of low grade lymphoma. Many clinical characteristics of low grade lymphoma in Korea differed from those of Western countries, especially in the incidence, therapeutic outcome and prognostic factors. In Korea, although the general incidence of low grade lymphoma is relatively low, the relative number of mucosa-associated lymphoid tissue lymphoma (MALToma) is very high, and the overall survival rate is better than that reported of Western countries. Thus, further investigation on treatment outcome and prognosis of low grade lymphoma entities, other than mucosa-associated lymphoid tissue lymphoma, are warranted.
Adolescent
;
Adult
;
Aged
;
Female
;
Human
;
Immunophenotyping
;
Lymphoma, Low-Grade/mortality/pathology/*therapy
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Prognosis
;
Treatment Outcome
3.Clinicopathologic Characteristics and Therapeutic Outcomes of Primary Gastrointestinal Non-Hodgkin's Lymphomas in Central Anatolia, in Turkey.
Bulent ESER ; Bunyamin KAPLAN ; Ali UNAL ; Ozlem CANOZ ; Fevzi ALTUNTAS ; H Ismail SARI ; Ozlem ER ; Metin OZKAN ; Can KUCUK ; Makbule ARAR ; Sebnem GURSOY ; Mustafa CETIN
Yonsei Medical Journal 2006;47(1):22-33
Primary gastrointestinal lymphoma is a common presentation of non-Hodgkin's lymphoma. The main controversy arises when many aspects of its classification and management are under discussion, particularly regarding roles for surgical resection. The aim of this study was to evaluate clinicopathologic characteristics and the therapeutic outcome of primary gastrointestinal non-Hodgkin's lymphoma. We carried out a retrospective analysis of 74 patients who were presented to our center with histopathological diagnosis of primary gastro-intestinal non-Hodgkin's lymphoma between 1990 and 2001. All patients have been staged according to Lugano Staging System. For histopathological classification, International Working Formulation was applied. The treatment choice concerning the surgical or non-surgical management was decided by the initially acting physician. Treatment modalities were compared using the parameters of age, sex, histopathological results, stage, and the site of disease. Of the 74 patients, 31 were female and 43 were male, with a median age of 49 years (range 15-80). The stomach was the most common primary site and was seen in 51 of 74 patients (68.9%). The intermediate and high grade lymphomas constituted 91.9% of the all cases. In a median follow-up of 29 months (range 2-128), 20 out of 74 patients died. There was a three year overall survival rate in 65.4% of all patients. The three year overall survival rate was better in stage I and II1 patients who were treated with surgery plus chemotherapy (+/-RT) than those treated with chemotherapy alone (93.7% vs. 55.6%, p<0.05). The stage and presence of B symptoms affected the disease free survival and overall survival significantly, but the histopathologic grade only affected the overall survival. On the basis of these results, we suggest that surgical resection is necessary before chemotherapy in early stage (stage I and II1) patients with gastrointestinal non-Hodgkin's lymphomas because of the significant survival advantage it would bring to the patient.
Turkey/epidemiology
;
Treatment Outcome
;
Survival Rate
;
Retrospective Studies
;
Neoplasm Staging
;
Middle Aged
;
Male
;
Lymphoma, Non-Hodgkin/mortality/*pathology/*therapy
;
Humans
;
Gastrointestinal Diseases/mortality/*pathology/*therapy
;
Female
;
Combined Modality Therapy/adverse effects
;
Aged, 80 and over
;
Aged
;
Adult
;
Adolescent
4.Treatment of early stage primary tonsil non-Hodgkin's lymphoma.
Yuan-hong GAO ; Ye-xiong LI ; Lu-jun ZHAO ; Zhi-yong YUAN ; Xin-fan LIU ; Zi-hao YU
Chinese Journal of Hematology 2003;24(4):190-192
OBJECTIVETo investigate the treatment for patients with early stage primary tonsil non-Hodgkin's lymphoma (NHL).
METHODSTwo hundred and thirteen patients with previously untreated early stage primary tonsil NHL were reviewed. All patients were pathologically confirmed. According to Ann Arbor classification, 35 patients were stage I, 178 stage II. The primary treatment for stage I was radiotherapy alone in 12 and combined modality therapy (CMT) in 23 patients. The primary treatment for stage II was radiotherapy alone in 57,chemotherapy alone in 2, and CMT in 119 patients.
RESULTSThe 5-year overall survival, cancer specific survival (CSS) AND disease-free survival (DFS) for the early stage primary tonsil non-Hodgkin's lymphoma were 65%, 70% and 61%, respectively. The 5-year CSS was 63% for the radiotherapy alone group and 72% for the CMT group (p = 0.064), and the 5-year DFS were 56% for the radiotherapy alone group and 62% for the CMT group. For patients with stage I disease, The 5-year CSS were 100% in both radiotherapy alone and CMT groups, and the 5-year DFS were 100% and 80% in these two groups (p = 0.148), respectively. There was no significant difference of efficacy between the two treatment s for the patients with stage I disease. For the patients with stage II disease, the 5-year CSS was 58% in radiotherapy alone group and 66% in CMT group (p = 0.051). However, CMT significantly improved DFS in stage II disease, with a 5-year DFS of 46% for radiotherapy alone and 60% for CMT (P = 0.046).
CONCLUSIONPatients with stage I tonsil non-Hodgkin's lymphoma treated with radiotherapy alone or CMT can achieve an excellent outcome. CMT significantly improve the DFS in stage II patients. There was a trend that CMT improved the survival rates in the patient with early stage disease. It was suggested that CMT should be used for the patients with early stage primary tonsil non-Hodgkin's lymphoma.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Combined Modality Therapy ; Female ; Humans ; Lymphoma, Non-Hodgkin ; mortality ; pathology ; therapy ; Male ; Middle Aged ; Neoplasm Staging ; Retrospective Studies ; Survival Rate ; Tonsillar Neoplasms ; mortality ; pathology ; therapy
5.Primary Lymphoma of Bone: Survival and Prognosis.
Jun Yong CHOI ; Jee Sook HAHN ; Chang Ok SUH ; Woo Ick YANG
The Korean Journal of Internal Medicine 2002;17(3):191-197
BACKGROUND: Primary lymphoma of bone is a rare disease. There is yet no systematical evaluation of primary lymphoma of bone in Korea. Here we report our experience of sixteen cases with primary lymphoma of bone focusing on the survival. METHODS: Sixteen cases, collected for 13 years, were evaluated on the clinical presentation, histologic subtype, stage and treatment outcomes of the primary bone lymphoma. RESULTS: The most common presenting complaint was bone pain. Malignant lymphoma of bone involved a wide variety of sites, the most prevalent site of which in this study was the spine. Most of the cases were in the diffuse large B-cell category. The clinical stage of lymphoma was IEA in two cases, IIEA in three cases, IVEA in five cases and IVEB in three cases. All treated cases received systemic chemotherapy and ten cases among them were treated with combined modality therapy. Median overall survival was not reached after median follow-up period of 28 months and five-year overall survival rate was 54%. CONCLUSION: More promising therapeutic strategies are needed for survival improvement on more accumulated cases.
Adolescent
;
Adult
;
Aged
;
Bone Neoplasms/*mortality/pathology/therapy
;
Child
;
Child, Preschool
;
Female
;
Human
;
Infant
;
Korea/epidemiology
;
Lymphoma/*mortality/pathology/therapy
;
Male
;
Middle Age
;
Neoplasm Staging
;
Prognosis
;
Retrospective Studies
;
Survival Rate
6.Analyzing of prognosis of intestinal T-cell lymphoma.
Wenyan ZHANG ; Gandi LI ; Weiping LIU ; Xingchang REN ; Huan XU
Chinese Journal of Pathology 2002;31(4):295-299
OBJECTIVETo investigate the roles of different clinicopathological features and expression of EBV genome in prognosis of intestinal T-cell lymphoma (ITCL).
METHODSPolymerase chain reaction for TCR-gamma gene rearrangement, in situ hybridization for EBER1/2 and immunohistochemical staining for CD4, CD8, CD45RO, CD56, TIA-1 were investigated and all patients followed-up. The LMP-1 expression was determined in forty-two ITCLs cases. The relationship between clinical data, different clinicopathological features, expression of EBV genome and prognosis were analyzed by SPSS10.0 program.
RESULTS(1) All 42 cases of ITCL had an extremely poor prognosis with a median survival of 3.0 months, of which the one year survival rate and two year survival rate being 30% and 22% respectively. (2) The patients without TCR-gamma gene rearrangements showed poorer prognosis than those with TCR-gamma gene rearrangements, and the patients who received operation and chemotherapy showed better prognosis than those who only received operation (P < 0.05). (3) No significant prognostic factor for ITCLs was determined.
CONCLUSIONThe special clinicopathological features of ITCL could be due to the cytotoxic function and the role of EBV infection in the pathogenesis of ITCL.
Adolescent ; Adult ; Child ; Female ; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor ; Humans ; Intestinal Neoplasms ; mortality ; pathology ; therapy ; Lymphoma, T-Cell ; mortality ; pathology ; therapy ; Male ; Middle Aged ; Prognosis ; Survival Rate
7.Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study.
Seong Jun LEE ; Cheol Won SUH ; Soon Il LEE ; Won Seog KIM ; Won Sik LEE ; Hyo Jung KIM ; Chul Won CHOI ; Jin Seok KIM ; Ho Jin SHIN
The Korean Journal of Internal Medicine 2014;29(3):352-360
BACKGROUND/AIMS: In Asia, the incidence of non-Hodgkin lymphoma (NHL) has increased in recent decades. Waldeyer's ring (WR) is the most common site of NHL involving the head and neck. In this study, the pathological distribution of WR-NHL and its clinical features were analyzed retrospectively. METHODS: From January 2000 through December 2010, we analyzed the medical records of 328 patients from nine Korean institutions who were diagnosed with WR-NHL. RESULTS: The study group comprised 197 male and 131 female patients with a median age of 58 years (range, 14 to 89). The rate of localized disease (stage I/II) was 64.9%, and that of low-risk disease (low/low-intermediate, as defined by the International Prognostic Index) was 76.8%. Diffuse large B-cell lymphoma (DLBCL; 240 patients, 73.2%) was the most common pathologic subtype, followed by peripheral T-cell lymphoma (14 patients, 4.3%) and nasal NK/T-cell lymphoma (14 patients, 4.3%). WR-NHL occurred most frequently in the tonsils (199 patients, 60.6%). Extranodal involvement was greater with the T-cell subtype (20 patients, 42.5%) compared with the B-cell subtype (69 patients, 24.5%). Multivariate analyses showed that age > or = 62 years, T-cell subtype, and failure to achieve complete remission were significant risk factors for overall survival. CONCLUSIONS: DLBCL was found to have a higher incidence in Korea than those incidences reported by other WR-NHL studies. T-cell lymphoma occurred more frequently than did follicular lymphoma. T-cell subtype, age > or = 62 years, and complete remission failure after first-line treatment were significant poor prognostic factors for overall survival according to the multivariate analysis.
Adolescent
;
Adult
;
Age Factors
;
Aged
;
Aged, 80 and over
;
Disease-Free Survival
;
Female
;
Head and Neck Neoplasms/mortality/*pathology/therapy
;
Humans
;
Incidence
;
Kaplan-Meier Estimate
;
Lymphoma, Extranodal NK-T-Cell/pathology
;
Lymphoma, Large B-Cell, Diffuse/pathology
;
Lymphoma, Non-Hodgkin/mortality/*pathology/therapy
;
Lymphoma, T-Cell, Peripheral/pathology
;
Male
;
Middle Aged
;
Multivariate Analysis
;
Neoplasm Staging
;
Proportional Hazards Models
;
Recurrence
;
Remission Induction
;
Republic of Korea
;
Retrospective Studies
;
Risk Factors
;
Time Factors
;
Treatment Outcome
;
Young Adult
8.Prognostic value of early treatment response in children with acute lymphoblastic leukemia: a single institution experience in Shanghai, China.
Li-Jun TIE ; Long-Jun GU ; De-Lian SONG ; Li-Min JIANG ; Hui-Liang XUE ; Jing-Yan TANG ; Lu DONG ; Ci PAN ; Jing CHEN ; Hui YE ; Jing CHEN
Chinese Journal of Contemporary Pediatrics 2009;11(1):5-9
OBJECTIVEEarly response to therapy is one of the most important prognostic factors in childhood acute lymphoblastic leukemia (ALL). This study aimed to assess the prognostic value of morphological assessment of bone marrow blasts during remission induction and determination of minimal residual disease (MRD) after remission induction.
METHODSFrom January 1998 to May 2003, 193 children with newly diagnosed ALL were enrolled on the ALL-XH-99 protocol. Blast cell count in the bone marrow was examined on day 19 of remission induction and by the completion of remission induction. MRD was measured with the flow cytometry. Event-free survival (EFS) was estimated by Kaplan-Meier analysis and the distributions of EFS were compared using the log-rank test. A Cox proportional hazards model was used to identify independent prognostic factors.
RESULTSThe 4-year EFS was significantly worse in patients with > or = 5% lymphoblasts in the bone marrow on day 19 as compared to those with <5% lymphoblasts on that date (42.59%+/- 14.28% vs 74.24%+/- 6.67%; p< 0.01). The 4-year EFS was significantly worse in patients with any amount of lymphoblasts in the bone marrow on the remission date as compared to that of other patients with no morphologically identifiable blasts (63.47%+/-9.23% vs 76.41%+/- 6.09%; p<0.05). The patients with MRD <0.01 had significantly better outcome than those with a level > or = 0.01% (15-month EFS:94.44%+/-5.40% vs 23.81%+/- 20.26%; p<0.01).
CONCLUSIONSEarly treatment response as assessed by morphological examination or minimal residual leukemia determination by flow cytometry has important prognostic significance, and can be performed in a resource-poor patient population.
Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Male ; Neoplasm, Residual ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; drug therapy ; mortality ; pathology ; Prognosis ; Proportional Hazards Models ; Treatment Outcome
9.Comparison of curative effect of autologous peripheral blood stem cell transplantation versus bone marrow transplantation for acute leukemia.
Yi-Zhuo ZHANG ; Bo-Long ZHANG ; Shan-Qian YAO ; Hai-Chuan LIU ; Fang-Ding LOU ; Chun-Ji GAO ; Xiao-Ping HAN ; Xiao-Xiong WU ; Yu ZHAO ; Quan-Shun WANG ; Yu JING ; Miao ZHANG ; Hai-Jie JIN ; Zi-Jiang SHI ; Wan-Ming DA
Journal of Experimental Hematology 2003;11(1):81-85
To compare the clinical outcome of autologous peripheral blood stem cell transplantation (APBSCT) and autologous bone marrow transplantation (ABMT) in treatment of patients with acute leukemia in first remission, 41 patients received APBSCT, 17 patients received unpurged ABMT and 30 patients received purged ABMT. The results showed that hematopoietic recovery was significantly earlier after APBSCT than that after purged or unpurged ABMT. The 3-year disease-free survival (DFS), relapse rate (RR) and transplant-related mortality (TRM) for all patients of 3 groups were 51.7%, 41.7% and 6.8%, respectively. DFS and RR were significantly influenced by disease types (ALL or AML) and intervals between diagnosis and CR(1) or CR(1) and transplant. The main causes of transplant-related death were infection and hemorrhage. After APBSCT, DFS, RR and TRM were 48.4%, 43.9% and 4.9%, respectively, and did not differ significantly from those found in unpurged ABMT (47.1%, 45.6% and 11.8%) or purged ABMT (66.5%, 29.6% and 6.7%). It is concluded that the clinical outcome of APBSCT is similar to unpurged or purged ABMT but APBSCT allows faster recovery of hematopoiesis and needs less transfusion support.
Acute Disease
;
Adolescent
;
Adult
;
Bacterial Infections
;
etiology
;
mortality
;
Bone Marrow Purging
;
Bone Marrow Transplantation
;
adverse effects
;
Child
;
Disease-Free Survival
;
Female
;
Follow-Up Studies
;
Hemorrhage
;
etiology
;
mortality
;
Humans
;
Leukemia
;
pathology
;
therapy
;
Leukemia, Erythroblastic, Acute
;
pathology
;
therapy
;
Leukemia, Monocytic, Acute
;
pathology
;
therapy
;
Leukemia, Myeloid, Acute
;
pathology
;
therapy
;
Leukemia, Myelomonocytic, Acute
;
pathology
;
therapy
;
Leukemia, Promyelocytic, Acute
;
pathology
;
therapy
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local
;
Peripheral Blood Stem Cell Transplantation
;
adverse effects
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
pathology
;
therapy
;
Remission Induction
;
Survival Rate
;
Transplantation, Autologous
10.Clinical features and prognosis of children with mature B-cell non-Hodgkin's lymphoma: an analysis of 28 cases.
Zai-Sheng CHEN ; Yong-Zhi ZHENG ; Yi-Qiao CHEN ; Qin-Li GAO ; Jian LI ; Jian-Zhen SHEN
Chinese Journal of Contemporary Pediatrics 2018;20(6):470-474
OBJECTIVETo study the clinical features and treatment outcome of children with mature B-cell non-Hodgkin's lymphoma (B-NHL).
METHODSA total of 28 previously untreated children with mature B-NHL were enrolled and given the chemotherapy regimen of CCCG-B-NHL-2010. Among them, 20 were given rituximab in addition to chemotherapy. The children were followed up for 31 months (ranged 4-70 months). A retrospective analysis was performed for the clinical features of these children. The Kaplan-Meier method was used for survival analysis. A univariate analysis was performed to investigate the prognostic factors.
RESULTSAmong the 28 children, 17 (61%) had Burkitt lymphoma, 8 (29%) had diffuse large B-cell lymphoma (DLBCL), and 3 (11%) had unclassifiable B-cell lymphoma. As for the initial symptom, 13 (46%) had cervical mass, 10 (36%) had maxillofacial mass, 9 (32%) had hepatosplenomegaly, 5 (18%) had abdominal mass, and 5 (18%) had exophthalmos. Of all children, 14 had a lactate dehydrogenase (LDH) level of <500 IU/L, 3 had a level of 500-1 000 IU/L, and 11 had a level of ≥ 1 000 IU/L. After two courses of chemotherapy, 21 children achieved complete remission and 7 achieved partial remission. At the end of follow-up, 24 achieved continuous complete remission and 4 experienced recurrence. The 2-year event-free survival rate was (85.7± 6.6)%. The children with bone marrow infiltration suggested by bone marrow biopsy, serum LDH ≥500 IU/L, and bone marrow tumor cells >25% had a low 2-year cumulative survival rate.
CONCLUSIONSThe CCCG-B-NHL 2010 chemotherapy regimen combined with rituximab has a satisfactory effect in the treatment of children with B-NHL. Bone marrow infiltration on bone marrow biopsy is associated with poor prognosis.
Antineoplastic Combined Chemotherapy Protocols ; administration & dosage ; Bone Marrow ; pathology ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Lymphoma, B-Cell ; diagnosis ; drug therapy ; mortality ; pathology ; Male ; Prognosis ; Progression-Free Survival ; Retrospective Studies ; Rituximab ; administration & dosage ; Treatment Outcome